PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Net income growth under 50% of GNPX's 39.46%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-22.93%
Negative yoy D&A while GNPX is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
18.38%
Deferred tax of 18.38% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-40.28%
Both cut yoy SBC, with GNPX at -65.23%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Slight usage while GNPX is negative at -10.11%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
Lower AP growth vs. GNPX's 357.46%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
300.21%
Some yoy usage while GNPX is negative at -23.70%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-40.28%
Negative yoy while GNPX is 357.46%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Operating cash flow growth above 1.5x GNPX's 4.89%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
19.38%
Some CapEx rise while GNPX is negative at -4.43%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
We have some outflow growth while GNPX is negative at -24.09%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
98.29%
We have mild expansions while GNPX is negative at -4.43%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
684.38%
Issuance growth of 684.38% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.